If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.



Biotech firms managed to go public in rocky year

by Ann M. Thayer
December 5, 2016 | A version of this story appeared in Volume 94, Issue 48

Notable IPOs in 2016
Table of notable IPOs in 2016.
Investors backed biotech firms pursuing CRISPR and cancer.IPO = Initial public offering of stock.
Source: Company data

The 2016 U.S. market for initial public offerings of stock “will go down as the least active year since the financial crisis and will most likely trail both 2008 and 2009 in terms of proceeds raised,” according to the IPO tracking firm Renaissance Capital.

Biotechs emerged as a bright spot. True, after nearly two years of strong fundraising, the biotech market cooled halfway through 2015 and remained down for 2016. But biotech firms still managed to account for all eight of the IPOs held in the first quarter. Moreover, offerings picked up in subsequent quarters and biotech companies made up about 40% of roughly 110 IPOs anticipated for the year.

Myovant Sciences, formed around just two drug candidates from Takeda Pharmaceutical, raised $218 million. Other notable IPOs of more than $100 million were from the Chinese firms BeiGene and Hutchinson China Meditech. Of the three, only BeiGene is outperforming its offering price—by more than 30%. Share prices have also risen substantially for AveXis, Protagonist Therapeutics, and Reata Pharmaceuticals.

Three start-ups focused on CRISPR/Cas9 gene editing technology—Editas Medicine, Intellia Therapeutics, and Crispr Therapeutics—went public this year. But share prices for all three are near where they started because of an ongoing dispute over CRISPR patent rights.


This article has been sent to the following recipient:

Chemistry matters. Join us to get the news you need.